GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » ROE %

DarioHealth (DarioHealth) ROE % : -90.57% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is DarioHealth ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DarioHealth's annualized net income for the quarter that ended in Dec. 2023 was $-57.14 Mil. DarioHealth's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $63.09 Mil. Therefore, DarioHealth's annualized ROE % for the quarter that ended in Dec. 2023 was -90.57%.

The historical rank and industry rank for DarioHealth's ROE % or its related term are showing as below:

DRIO' s ROE % Range Over the Past 10 Years
Min: -276.74   Med: -126.35   Max: -75.14
Current: -83.32

During the past 12 years, DarioHealth's highest ROE % was -75.14%. The lowest was -276.74%. And the median was -126.35%.

DRIO's ROE % is ranked worse than
90.18% of 611 companies
in the Healthcare Providers & Services industry
Industry Median: 4.13 vs DRIO: -83.32

DarioHealth ROE % Historical Data

The historical data trend for DarioHealth's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth ROE % Chart

DarioHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.51 -125.18 -135.02 -75.14 -86.04

DarioHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.74 -67.49 -88.20 -85.94 -90.57

Competitive Comparison of DarioHealth's ROE %

For the Health Information Services subindustry, DarioHealth's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DarioHealth's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's ROE % distribution charts can be found below:

* The bar in red indicates where DarioHealth's ROE % falls into.



DarioHealth ROE % Calculation

DarioHealth's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-59.427/( (79.999+58.144)/ 2 )
=-59.427/69.0715
=-86.04 %

DarioHealth's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-57.14/( (68.035+58.144)/ 2 )
=-57.14/63.0895
=-90.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


DarioHealth  (NAS:DRIO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-57.14/63.0895
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-57.14 / 14.464)*(14.464 / 101.447)*(101.447 / 63.0895)
=Net Margin %*Asset Turnover*Equity Multiplier
=-395.05 %*0.1426*1.608
=ROA %*Equity Multiplier
=-56.33 %*1.608
=-90.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-57.14/63.0895
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-57.14 / -56.884) * (-56.884 / -56.86) * (-56.86 / 14.464) * (14.464 / 101.447) * (101.447 / 63.0895)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0045 * 1.0004 * -393.11 % * 0.1426 * 1.608
=-90.57 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


DarioHealth ROE % Related Terms

Thank you for viewing the detailed overview of DarioHealth's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


DarioHealth (DarioHealth) Business Description

Traded in Other Exchanges
N/A
Address
18 W. 18th Street, New York, NY, USA, 10011
DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.
Executives
Jon H. Kaplan director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael director, officer: Chief Executive Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher officer: Chief Operating Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen officer: GM MSK 8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis director 8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked director 8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer director 8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson officer: President, GM of North America C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi director C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david officer: Chief Financial Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller director 8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry officer: See Remarks 15 ROCKRIDGE RD, LARCHMONT NY 10538-3918